AYTU BIOPHARMA, INC Income Statement
AYTU|12 years of annual SEC 10-K data (FY2012-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 12 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$66M
FY2025
Gross Profit
$46M
69.0% gross margin
Operating Income
-$8M
FY2025
Net Income
-$14M
FY2025
AYTU BIOPHARMA, INC reported $66M in revenue and $14M in net loss for FY2025. Revenue has grown at a 125.0% compound annual rate over the past 13 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -71.5% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M | $27.6M | $3.7M | $3.2M | $2.6M | $261.8K | $5.3K | $1.8K |
| Cost of Revenue | $20.6M | $16.1M | $40.8M | $44.4M | $36.4M | $8.3M | $2.1M | $1.4M | $957.1K | $88.1K | - | - |
| Gross Profit | $45.8M | $49.1M | $66.6M | $52.3M | $29.2M | $19.4M | - | - | - | - | - | - |
| SG&A Expense | $17.4M | $20.0M | $28.6M | $31.2M | $25.5M | $34.8M | $17.7M | $17.4M | $8.5M | $4.0M | $341.5K | $33.6K |
| R&D Expense | $1.3M | $2.8M | $4.1M | $12.7M | $5.6M | $1.7M | $167.6K | $959.9K | $6.1M | $3.2M | - | - |
| Operating Income | -$7.8M | -$1.6M | -$17.1M | -$109.9M | -$58.9M | -$21.1M | -$19.7M | -$20.1M | -$21.7M | -$7.6M | -$543.3K | -$56.4K |
| Interest Expense | - | - | - | $900.0K | - | $2.6M | $749.4K | $2.5M | $5.5M | $115.0K | $25.2K | $3.3K |
| Income Tax | $437.0K | $2.1M | $0 | -$110.0K | $259.0K | $0 | $0 | $0 | $0 | -$23.9K | - | - |
| Net Income | -$13.6M | -$15.8M | -$17.1M | -$108.8M | -$58.3M | -$13.6M | -$10.2M | -$22.5M | -$28.2M | -$7.7M | -$568.2K | -$59.7K |
| EPS (Basic) | -$2.86 | -$5.11 | -$74.01 | -$3.48 | - | - | - | - | - | - | - | - |
| EPS (Diluted) | - | - | -$74.01 | -$3.48 | -$3.01 | -$3.48 | -$48.30 | -$323.70 | -$10.07 | -$0.80 | -$0.01 | -$0.03 |
| Shares Outstanding | 6.0M | 5.5M | 1.9M | 27.5M | 12.6M | 17.5M | 41.2K | 187.1K | 1.2M | 7.9M | 4.9M | 4.7M |
| Gross Margin | 69.0% | 75.3% | 62.0% | 54.1% | 44.5% | 70.0% | - | - | - | - | - | - |
| Operating Margin | -11.8% | -2.4% | -15.9% | -113.7% | -89.7% | -76.5% | -538.2% | -624.7% | -847.0% | -2915.5% | -10348.2% | -3220.3% |
| Profit Margin | -20.4% | -24.3% | -15.9% | -112.5% | -88.8% | -49.3% | -278.4% | -698.7% | -1099.7% | -2950.3% | -10822.9% | -3410.0% |